Last updated: 2 March 2023 at 4:45pm EST

Robert Ingram Net Worth




The estimated Net Worth of Robert Alexander Ingram is at least $3.51 million dollars as of 30 September 2020. Mr. Ingram owns over 5,000 units of Biocryst Pharmaceuticals stock worth over $38,650 and over the last 21 years he sold BCRX stock worth over $3,321,950. In addition, he makes $154,088 as Independent Chairman of the Board at Biocryst Pharmaceuticals.

Mr. Ingram BCRX stock SEC Form 4 insiders trading

Robert has made over 15 trades of the Biocryst Pharmaceuticals stock since 2008, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of BCRX stock worth $152,300 on 30 September 2020.

The largest trade he's ever made was buying 50,000 units of Biocryst Pharmaceuticals stock on 22 May 2019 worth over $110,500. On average, Robert trades about 1,185 units every 26 days since 2003. As of 30 September 2020 he still owns at least 5,000 units of Biocryst Pharmaceuticals stock.

You can see the complete history of Mr. Ingram stock trades at the bottom of the page.





Robert Ingram biography

Robert A. Ingram serves as Independent Chairman of the Board of the Company. Mr. Ingram was appointed to the Board in August 2015 and was elected Chairman of the Board in May 2017. Mr. Ingram joined Hatteras Venture Partners, a venture capital firm formed to invest primarily in early stage companies with a focus on biopharmaceuticals, medical devices, diagnostics, healthcare IT, and related opportunities in human medicine, as a General Partner in January 2007. He began his career in the pharmaceutical industry as a professional sales representative and rose through a series of roles with increasing responsibility to ultimately become CEO and Chairman of GlaxoWellcome, a pharmaceutical company. He co-led the merger and integration that formed GlaxoSmithKline (GSK) in December 2000. He subsequently served as the Chief Operating Officer and President of Pharmaceutical Operations at GSK from January 2001 to January 2003. He served as Vice Chairman Pharmaceuticals of GSK, acting as a special advisor to GSK's corporate executive team, until January 1, 2010. Mr. Ingram is Chairman of the boards of Novan, Inc., a late-stage pharmaceutical company focused on dermatology, and Viamet Pharmaceuticals Inc., a private company focused on anti-infective research. He recently retired as Chairman of the Cree Board. Mr. Ingram also serves as a member of the board of directors of HBM Healthcare Investments, Ltd., a publicly traded Swiss investment company. Mr. Ingram graduated from Eastern Illinois University with a B.S. degree in Business Administration. In addition to his professional responsibilities, Mr. Ingram formed and chaired the CEO Roundtable on Cancer at the request of former President George H. W. Bush, and he is a member of numerous other civic and professional organizations.

What is the salary of Robert Ingram?

As the Independent Chairman of the Board of Biocryst Pharmaceuticals, the total compensation of Robert Ingram at Biocryst Pharmaceuticals is $154,088. There are 9 executives at Biocryst Pharmaceuticals getting paid more, with Jon Stonehouse having the highest compensation of $2,284,300.



How old is Robert Ingram?

Robert Ingram is 77, he's been the Independent Chairman of the Board of Biocryst Pharmaceuticals since 2017. There are no older and 22 younger executives at Biocryst Pharmaceuticals.

What's Robert Ingram's mailing address?

Robert's mailing address filed with the SEC is 280 S. MANGUM STREET, SUITE 350, DURHAM, NC, 27701.

Insiders trading at Biocryst Pharmaceuticals

Over the last 24 years, insiders at Biocryst Pharmaceuticals have traded over $76,362,383 worth of Biocryst Pharmaceuticals stock and bought 4,042,003 units worth $20,848,654 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Brothers Life Sciences Capi... et Carl L Gordon. On average, Biocryst Pharmaceuticals executives and independent directors trade stock every 31 days with the average trade being worth of $542,329. The most recent stock trade was executed by Amy E Mc Kee on 24 June 2024, trading 8,600 units of BCRX stock currently worth $54,352.



What does Biocryst Pharmaceuticals do?

biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.



What does Biocryst Pharmaceuticals's logo look like?

Biocryst Pharmaceuticals Inc. logo

Complete history of Mr. Ingram stock trades at Biocryst Pharmaceuticals, Cree, Novan Inc, Regeneron Pharmaceuticals, Edwards Lifesciences Corp, Lowe`s Cos et Black Diamond Therapeutics Inc

Date
#
Société
Initié
Trans.
Transaction
Actions Prix par action Prix ​​total Actions après Source
30 Sep 2020 Robert Alexander Ingram
Acheter 5,000 $30.46 $152,300
30 Sep 2020
5,000
18 Nov 2019 Robert Alexander Ingram
Directeur
Acheter 20,000 $1.45 $29,000
18 Nov 2019
48,088
22 May 2019 Robert Alexander Ingram
Directeur
Acheter 50,000 $2.21 $110,500
22 May 2019
169,777
28 Sep 2018 Robert Alexander Ingram
Directeur
Acheter 50,000 $2.84 $142,000
28 Sep 2018
119,777
25 Aug 2017 Robert Alexander Ingram
Directeur
Acheter 12,000 $4.57 $54,840
25 Aug 2017
69,777
30 Aug 2018 Robert Alexander Ingram
Directeur
Exercice d'option 4,000 $30.92 $123,680
30 Aug 2018
76,950
1 Dec 2015 Robert Alexander Ingram
Directeur
Exercice d'option 3,750 $14.71 $55,163
1 Dec 2015
52,596
1 Dec 2015 Robert Alexander Ingram
Directeur
Exercice d'option 3,750 $14.71 $55,163
1 Dec 2015
52,596
6 Mar 2009 Robert Alexander Ingram
Directeur
Acheter 1,000 $18.95 $18,950
6 Mar 2009
4,750
22 May 2015 Robert Alexander Ingram
Directeur
Exercice d'option 6,667 $293.53 $1,956,965
22 May 2015
6,667
31 Jul 2014 Robert Alexander Ingram
Directeur
Vente 12,500 $90.26 $1,128,250
31 Jul 2014
30,541
25 May 2012 Robert Alexander Ingram
Directeur
Vente 15,000 $87.72 $1,315,800
25 May 2012
36,856
9 May 2011 Robert Alexander Ingram
Directeur
Vente 10,000 $87.79 $877,900
9 May 2011
46,302
27 May 2010 Robert Alexander Ingram
Directeur
Exercice d'option 8,000 $21.13 $169,040
27 May 2010
8,000
21 May 2008 Robert Alexander Ingram
Directeur
Exercice d'option 8,000 $17.96 $143,680
21 May 2008
8,000


Biocryst Pharmaceuticals executives and stock owners

Biocryst Pharmaceuticals executives and other stock owners filed with the SEC include: